Tag: Aimmune Therapeutics

September 13, 2019 Off

Aimmune gets FDA Allergenic Products Advisory committee’s support the use of its Palforzia for peanut allergy

By BusinessWire

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy.